WINDLAS Windlas Biotech Q4 FY25 results (Jan–Mar 2025) and concall
Windlas Biotech delivered robust financial results for Q4 and FY25, driven by strong growth across its CDMO, Trade Generics, and Exports verticals, achieving record revenue and EPS. The company maintained efficient working capital and strong liquidity. While the new injectable facility is still in its ramp-up phase and impacting current margins, management remains optimistic about its future contribution and margin expansion as it stabilizes and Plant 6 becomes operational.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|
| Revenue | 175 | 187 | 195 | 203 |
| EBITDA | 21 | 23 | 25 | 26 |
| Net profit | 13 | 16 | 16 | 16 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
